In 2022, there were 565 reported deaths due to tuberculosis, a significant decrease from 5,217 deaths in 1970. This statistic depicts the number of deaths due to tuberculosis in the United States from 1960 to 2022. Tuberculosis Disease Of all infectious diseases, tuberculosis (TB) remains one of the most deadly worldwide. TB is a contagious lung disease caused by bacteria and passed through the air from an infected person to others. It often remains dormant for a few years before presenting as an active case in about five percent of latent cases. Common symptoms include coughing, including coughing up blood, and unexplained weight loss as the infection begins to spread throughout the body. Without antibiotic treatment, about one third of those with an active infection will die within two years and another third within five years. At-risk Populations Although the death rate for TB in the United States and other developed countries has remained relatively low over the past thirty years, other countries are more heavily burdened by this disease. The regions of Africa and South-East Asia have the highest number of tuberculosis deaths worldwide. In 2022, there were around 632 thousand deaths due to tuberculosis in South-East Asia, compared to just 35 thousand in the Americas.

In 2023, there were around 15.5 deaths due to tuberculosis per 100,000 population worldwide. In comparison, the tuberculosis mortality rate in the year 2010 was 28.4 per 100,000 population. This statistic shows the mortality rate of tuberculosis worldwide from 2010 to 2023.

In 2023, there were around 1.25 million deaths due to tuberculosis worldwide. This statistic shows the number of tuberculosis deaths worldwide from 2010 to 2023.

In Canada, the death rate for tuberculosis (TB) has remained stable for the past twenty years. In 2023, around *** out of 100 thousand Canadians died from TB. This statistic displays the age-standardized death rates for tuberculosis in Canada from 2000 to 2023. Tuberculosis Tuberculosis (TB) is a lung disease caused by a contagious bacterium spread through the air and was the deadliest communicable disease worldwide in 2019. The disease often remains dormant for a few years after infection, after which about **** percent of those infected will develop active TB disease. Although reported cases have remained low in developed countries, many developing countries still struggle with higher rates. Moreover, individuals with HIV are at higher risk of developing and dying from an active TB infection, especially in high-burden countries. Prevention, treatment, and control Nowadays, antibiotics are the primary treatment modality for those infected with the bacterium causing TB. Efforts to reduce the burden of tuberculosis include enhancing prevention and control of cases of the disease, identification of risk factors, and treatment strategies for populations at risk of developing the active disease. Although reported cases have remained relatively low in Canada for the past thirty years, populations within the country at high risk include Indigenous peoples and foreign-born individuals.

Mortality from tuberculosis (ICD-10 A15-A19 equivalent to ICD-9 010-018). To reduce deaths from tuberculosis. Legacy unique identifier: P00489

BackgroundGlobally in 2016, 1.7 million people died of Tuberculosis (TB). This study aimed to estimate all-cause mortality rate, identify features associated with mortality and describe trend in mortality rate from treatment initiation.MethodA 5-year (2012–2016) retrospective analysis of electronic TB surveillance data from Kilifi County, Kenya. The outcome was all-cause mortality within 180 days after starting TB treatment. The risk factors examined were demographic and clinical features at the time of starting anti-TB treatment. We performed survival analysis with time at risk defined from day of starting TB treatment to time of death, lost-to-follow-up or completing treatment. To account for ‘lost-to-follow-up’ we used competing risk analysis method to examine risk factors for all-cause mortality.Results10,717 patients receiving TB treatment, median (IQR) age 33 (24–45) years were analyzed; 3,163 (30%) were HIV infected. Overall, 585 (5.5%) patients died; mortality rate of 12.2 (95% CI 11.3–13.3) deaths per 100 person-years (PY). Mortality rate increased from 7.8 (95% CI 6.4–9.5) in 2012 to 17.7 (95% CI 14.9–21.1) in 2016 per 100PY (Ptrend

Download reports and data on tuberculosis incidences in Massachusetts, including a 5-year summary and demographic breakouts.

Actual value and historical data chart for Uganda Tuberculosis Death Rate Per 100000 People

Actual value and historical data chart for Bangladesh Tuberculosis Death Rate Per 100000 People

Forecast: Number of Deaths Due to Tuberculosis (Excluding HIV Cases) in the US 2023 - 2027 Discover more data with ReportLinker!

Actual value and historical data chart for Norway Tuberculosis Death Rate Per 100000 People

BackgroundTuberculosis (TB) remains a significant global health issue, but its burden among children and adolescents under 15 years old is not well quantified. This study evaluates TB trends in this age group from 1990 to 2021 and projects future trends through 2040.MethodsWe used data from the Global Burden of Disease Study (GBD) 2021 to assess the incidence and mortality of TB in children and adolescents (under 15) from 1990 to 2021. A Bayesian age-period-cohort model was employed to project the TB burden.ResultsIn 2021, there were 799,047 new TB cases and 81,870 TB-related deaths among children, with an age-standardized incidence rate (ASIR) of 40.01 per 100,000 population and an age-standardized mortality rate (ASMR) of 4.16 per 100,000 population. From 1990 to 2021, the ASIR declined by 2.4% annually, while ASMR decreased by 4.19% per year. However, drug-resistant TB, especially extensively drug-resistant TB, increased significantly. The burden was highest in low-SDI regions, particularly among children under 5, who accounted for over 75% of TB-related deaths. Projections to 2040 indicate continued declines in ASIR and ASMR for all TB forms, including drug-resistant and TB-HIV co-infections.ConclusionSustained investment in TB control programs, particularly in low-SDI regions, is crucial. Addressing drug-resistant TB and TB-HIV co-infection should be prioritized in global public health strategies.

Background: Global progress towards reducing tuberculosis (TB) incidence and mortality has consistently lagged behind World Health Organization targets leading to a perception that large reductions in TB burden cannot be achieved. However, several recent and historical trials suggest that intervention efforts that are comprehensive and focused can have substantial epidemiological impact. We aimed to quantify the potential epidemiological impact of an intensive but realistic, community-wide campaign utilizing existing tools, and designed to achieve a "step change" in TB burden.

Methods: We developed a compartmental model of tuberculosis transmission in a mid-sized city in India, the country with the greatest absolute burden of TB worldwide. We modeled the impact of a campaign comprising one-time community-wide screening with treatment for TB disease and preventive therapy for latent TB infection (LTBI). This one-time intervention was followed by strengthening of tuberculosis-related health system achieved by leveraging the one-time campaign. We estimated the tuberculosis cases and deaths that could be averted over 10 years using this comprehensive approach and assessed the contributions of individual components of the intervention.

Results: A campaign that successfully screened 70% of the adult population for active and latent tuberculosis and subsequently reduced diagnostic and treatment delays and unsuccessful treatment outcomes by 50% was projected to avert 7,800 (95% range: 5,450 – 10,200) cases and 1,710 (1,290 – 2,180) tuberculosis-related deaths per 1 million population over 10 years. Of the total averted deaths, 33.5% (28.2 – 38.3) were attributable to inclusion of preventive therapy and 52.9% (48.4 - 56.9) to health system strengthening.

Conclusions: A one-time, community-wide mass campaign, comprehensively designed to detect, treat, and prevent tuberculosis with currently existing tools can have meaningful and long-lasting epidemiological impact. Successful treatment of LTBI is critical to achieving this result. Health system strengthening is essential to any effort to transform the TB response.

BackgroundTuberculosis (TB) mortality declined in the northern hemisphere over the last 200 years, but peaked during the Russian (1889) and the Spanish (1918) influenza pandemics. We studied the impact of these two pandemics on TB mortality.MethodsWe retrieved historic data from mortality registers for the city of Bern and countrywide for Switzerland. We used Poisson regression models to quantify the excess pulmonary TB (PTB) mortality attributable to influenza.ResultsYearly PTB mortality rates increased during both influenza pandemics. Monthly influenza and PTB mortality rates peaked during winter and early spring. In Bern, for an increase of 100 influenza deaths (per 100,000 population) monthly PTB mortality rates increased by a factor of 1.5 (95%Cl 1.4–1.6, p

BackgroundWe aimed to determine the trend of TB-related deaths during the COVID-19 pandemic.MethodsTB-related mortality data of decedents aged ≥25 years from 2006 to 2021 were analyzed. Excess deaths were estimated by determining the difference between observed and projected mortality rates during the pandemic.ResultsA total of 18,628 TB-related deaths were documented from 2006 to 2021. TB-related age-standardized mortality rates (ASMRs) were 0.51 in 2020 and 0.52 in 2021, corresponding to an excess mortality of 10.22 and 9.19%, respectively. Female patients with TB demonstrated a higher relative increase in mortality (26.33 vs. 2.17% in 2020; 21.48 vs. 3.23% in 2021) when compared to male. Female aged 45–64 years old showed a surge in mortality, with an annual percent change (APC) of −2.2% pre-pandemic to 22.8% (95% CI: −1.7 to 68.7%) during the pandemic, corresponding to excess mortalities of 62.165 and 99.16% in 2020 and 2021, respectively; these excess mortality rates were higher than those observed in the overall female population ages 45–64 years in 2020 (17.53%) and 2021 (33.79%).ConclusionThe steady decline in TB-related mortality in the United States has been reversed by COVID-19. Female with TB were disproportionately affected by the pandemic.

Tuberculosis is one of the most common causes of death globally.

By Saloni Dattani, Fiona Spooner, Hannah Ritchie and Max Roser

Data description:

In richer countries, the impact of tuberculosis has been reduced significantly over history, but in poorer parts of our world, it continues to be a major challenge even today: it causes an estimated 1.2 million deaths annually.

Tuberculosis is caused by the bacteria Mycobacterium tuberculosis.

The bacteria spreads through respiratory particles and tends to cause tuberculosis in people with risk factors such as undernourishment, HIV/AIDS, smoking, and existing chronic conditions.

The disease involves symptoms like coughing, fatigue and night sweats, and can damage the lungs, the brain, kidneys and other organs, which can be fatal.

But it is treatable with a combination of specific antibiotics. Without being diagnosed correctly, however, people do not receive the proper treatment. This leaves them vulnerable, and also increases the risk that antibiotic-resistant strains of the bacteria will develop, which are much more difficult and expensive to treat.

With greater effort to tackle its risk factors and improve testing and treatment for the disease, the world can relegate tuberculosis to history — not just in the richer parts of the world, but for everyone.

Data number 1: Tuberculosis is still common in many parts of the world In high-income countries, tuberculosis is largely a disease of the past. Since the beginning of the 20th century, its impact has been significantly reduced with the development of antibiotics and improvements in healthcare and living standards.

Data number 2: Tuberculosis kills over a million people annually, most of whom are adults Tuberculosis kills over a million people each year, as you can see in the chart. The chart shows that most of those who die from tuberculosis are adults.

Data number 3: Many people with tuberculosis are undiagnosed Although tuberculosis is typically a disease of the lungs, the bacteria can affect many organs in the body, and people who are infected don’t always have respiratory symptoms. Instead, they may experience weight loss, breathlessness, fever, or night sweats.

Data number 4: Antibiotic resistance is an important consideration during treatment People with tuberculosis require treatment with a specific combination of antibiotic medications that can kill the bacteria.

Data number 5: HIV increases the risk of developing tuberculosis An HIV infection is a major risk factor for developing tuberculosis.

Good luck

In 2022, the rate of death from tuberculosis in the U.S. was .2 per every 100,000 population, a significant decrease from a rate of six in 1960. This statistic depicts the death rate for tuberculosis in the United States from 1960 to 2022.

ObjectivesEstimate TB mortality rates, catalogue multiple causes on death certificates in which TB was reported and identify predictors of TB from reporting on death certificates in the State of Amazonas, Brazil, based on a multiple cause of death approach.MethodsThe death records of residents in the Amazonas state between 2006–2014 were analyzed and separated into three categories: TB not reported on the death certificate (TBNoR), TB reported as the underlying cause of death (TBUC) and TB reported as an associated cause of death (TBAC). Age standardized annual mortality rates for TBUC, TBAC and with TB reported (TBUC plus TBAC) were estimated for the State of Amazonas using the direct standardization method and World Health Organization 2000–2025 standard population. Mortality odds ratios (OR) for reporting of TBUC and TBAC were estimated using multinomial logistic regression.ResultsAge standardized annual TBUC and TBAC mortality rates ranged between 5.9–7.8/105 and 2.7–4.0/105, respectively. TBUC was associated with being a resident in the State capital (OR = 0.66), of female gender (OR = 0.87), having an education level of 8 to 11, or 12 or more school years (OR = 0.67 and 0.50 respectively), non-white race/skin color (OR = 1.38) and place of death reported as in the State capital (OR = 1.69). TBAC was related to the triennium in which death occurred (OR = 1.21 and 1.22 for the years 2009–2011 and 2012–2014 respectively), age (OR = 36.1 and 16.5 for ages 15–39 and 40–64 years respectively) and when death occurred in the State capital (OR = 5.8).ConclusionsTBUC was predominantly associated with predictors of unfavorable socioeconomic conditions and health care access constraints, whereas TBAC was mainly related to ages which were typical of high HIV disease incidence.

Actual value and historical data chart for Zimbabwe Tuberculosis Death Rate Per 100000 People

Deaths from tuberculosis. Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data